Form 4: Sionna Therapeutics CEO Sells Shares After Option Exercise

Sionna Therapeutics' President & CEO, Michael Cloonan, sold common stock acquired through option exercises as part of a pre-arranged 10b5-1 trading plan.

Summary

• Michael Cloonan, President & CEO of Sionna Therapeutics, Inc., executed transactions under a Rule 10b5-1 trading plan.
• On August 26, 2025, Cloonan exercised Non-Qualified Stock Options to acquire 17,574 shares of common stock at an exercise price of $6.11 per share.
• Immediately following the option exercise on August 26, 2025, 17,574 shares were sold at a weighted average price of $24.96 per share, with individual transaction prices ranging from $24.75 to $25.49.
• On August 27, 2025, Cloonan exercised Non-Qualified Stock Options to acquire 7,426 shares of common stock at an exercise price of $6.11 per share.
• Concurrently, on August 27, 2025, 7,426 shares were sold at a weighted average price of $25.0086 per share, with individual transaction prices ranging from $24.80 to $25.32.
• Following these transactions, Cloonan's direct beneficial ownership of common stock is 547,343 shares.
• The number of beneficially owned Non-Qualified Stock Options decreased from 210,568 to 203,142 after these exercises.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions (option exercises and sales) executed under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature and the significant profit realized from the option exercises suggest a neutral to slightly positive sentiment, as the insider is monetizing vested equity at a favorable price.

Positives

• The stock was sold at a significantly higher price ($24.96 $25.0086) compared to the option exercise price ($6.11), indicating substantial gains for the insider.
• Transactions were executed under a Rule 10b5-1 trading plan adopted on May 21, 2025, suggesting pre-scheduled activity rather than a discretionary sale based on new material non-public information.

Negatives

• President & CEO Michael Cloonan reduced his direct beneficial ownership of common stock by a total of 25,000 shares (17,574 on August 26, 2025, and 7,426 on August 27, 2025).

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the insider sale as a signal, though the pre-arranged 10b5-1 plan mitigates concerns about discretionary selling based on new information. The sale at a high price indicates value realization for the insider.
• Employees are not directly impacted by these specific transactions, though the CEO's equity holdings remain substantial.

Next Steps

• Ongoing vesting of remaining Non-Qualified Stock Options in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date.

Key Dates

Recommendation

This Form 4 filing details pre-scheduled insider transactions (option exercises and subsequent sales) by the President & CEO under a Rule 10b5-1 plan. While the insider is realizing significant gains by selling shares at prices substantially above the exercise price, the pre-planned nature of the transactions suggests they are not based on new material non-public information. Therefore, this filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate, pending further fundamental analysis of the company's performance and outlook.

Keywords

Sionna Therapeutics, SION, insider trading, Form 4, stock options, CEO, Michael Cloonan, 10b5-1 plan, equity sales